Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5856 | 2768288-97-5 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Sipavibart is a recombinant human IgG1 monoclonal antibody that provides passive immunisation by binding the SARS-CoV-2 spike protein receptor binding domain (RBD). Sipavibart is long-acting, with amino acid substitutions to extend antibody half-life (YTE) and to reduce antibody effector function and potential risk of antibody-dependent enhancement of disease (TM). Sipavibart binds to the spike protein RBD of SARS-CoV-2 (BA.2), blocking RBD binding to the human ACE2 receptor. This results in a blockade of virus entry.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 20, 2025 | EMA | AstraZeneca AB | |
| Dec. 27, 2024 | PMDA | AstraZeneca K.K. |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | J06BD09 | ANTIINFECTIVES FOR SYSTEMIC USE IMMUNE SERA AND IMMUNOGLOBULINS IMMUNOGLOBULINS Antiviral monoclonal antibodies |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Pre-exposure prophylaxis of COVID-19 | indication | 840539006 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Spike glycoprotein | Glycoprotein | ANTIBODY BINDING | Kd | 10.68 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| CHEMBL5315011 | ChEMBL_ID |
| C5854470 | UMLSCUI |
| CHEBI:759701 | CHEBI |
| 12778 | INN_ID |
| 13905 | IUPHAR_LIGAND_ID |
| 977D2P9YYW | UNII |
| D12974 | KEGG_DRUG |
None